1. merck sharp & dohme b.v
  2. flugen inc
  3. scs boehringer ingelheim comm.v
  4. Search the database for deliberate release of GM medicinal products

Search the database for deliberate release of GM medicinal products

Displaying 1 - 1 of 1
EU record number Title Company / Sponsor Treated organism Genetic modification
B/BE/21/BVW7 Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors SCS Boehringer Ingelheim Comm.V Humans BI 1831169 is a recombinant live-attenuated Vesicular Stomatitis Virus (rVSV), modified to replace the VSV-G glycoprotein with the Lymphocytic Choriomeningitis Virus glycoprotein in order to minimize the potential of neurotoxicity for humans and skin disease in animals.